title: Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting?
authors.forename: J M
authors.initials: JM
authors.lastname: Khan
authors.forename: R D S
authors.initials: RD
authors.lastname: Watson
authors.forename: C
authors.initials: C
authors.lastname: Varma
authors.forename: T
authors.initials: T
authors.lastname: Millane
authors.forename: G Y H
authors.initials: GY
authors.lastname: Lip
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000592:standards*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D003327:Coronary Disease / Q000601:surgery*; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic / Q000592:standards*; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab